Valuation: Interpace Biosciences, Inc.

Market Cap 33.25M 29.7M 27.63M 25.13M 47.44M 3.22B 47.65M 332M 130M 1.64B 125M 122M 5.27B P/E 2024
6.84x
P/E 2025 1.39x
Enterprise Value 31.93M 28.52M 26.53M 24.13M 45.56M 3.09B 45.75M 319M 125M 1.58B 120M 117M 5.06B EV / Sales 2024
0.35x
EV / Sales 2025 0.11x
Free-Float
8.77%
Yield 2024 *
-
Yield 2025 -
1 week-0.41%
Current month-6.10%
1 month-7.69%
3 months-26.83%
6 months-47.83%
Current year-2.45%
1 week 6
Extreme 6
6.32
1 month 5.97
Extreme 5.9732
6.65
Current year 5.15
Extreme 5.15
12
1 year 4.03
Extreme 4.0275
12
3 years 2.22
Extreme 2.216625
17.7
5 years 2.22
Extreme 2.216625
48.5
10 years 2.22
Extreme 2.216625
990
Manager TitleAgeSince
Chief Executive Officer 64 2020-11-30
Director of Finance/CFO 34 2023-04-20
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Chairman 79 2016-06-20
Director/Board Member 73 2015-12-31
Director/Board Member 64 2020-01-21
Date Insider Type Main position Quantity % Market Cap. Importance
8/20/26 Free

Director

69,252 0.2501%
8/20/26 Exercice

Chief Financial Officer

1,385,045 5.0015%
8/20/26 Free

Director

69,252 0.2501%
Change 5-day change 1-year change 3-year change Capi.($)
0.00%-0.41%+22.91%+33.33% 33.25M
-1.87%-0.35%+10.60%+20.12% 110B
+1.37%+5.72%+8.66%+84.82% 97.66B
+2.54%-2.35%+136.73%+794.24% 57.76B
+1.84%-2.93%-11.21%+66.03% 26.71B
+0.07%-1.01%+25.48%+88.19% 25.49B
-0.65%+1.19%+12.33%+56.16% 25.32B
-0.48%+1.74%-17.83%0.00% 21.32B
+1.23%+2.00%+39.14%+357.16% 21.24B
+0.44%+14.89%+14.98%+88.19% 20.02B
Average +0.45%+1.78%+24.18%+158.83% 40.57B
Weighted average by Cap. +0.33%+1.65%+27.91%+175.39%

Financials

2024 2025
Net sales 46.93M 41.91M 38.99M 35.46M 66.96M 4.54B 67.24M 469M 184M 2.32B 176M 172M 7.43B 38.73M 34.59M 32.18M 29.27M 55.26M 3.75B 55.5M 387M 152M 1.91B 145M 142M 6.13B
Net income 6.7M 5.99M 5.57M 5.06M 9.56M 649M 9.6M 67.01M 26.26M 331M 25.17M 24.62M 1.06B 24.58M 21.95M 20.42M 18.57M 35.06M 2.38B 35.22M 246M 96.28M 1.21B 92.28M 90.27M 3.89B
Net Debt 4.4M 3.93M 3.65M 3.32M 6.27M 425M 6.3M 43.95M 17.22M 217M 16.5M 16.14M 696M -1.32M -1.18M -1.1M -999K -1.89M -128M -1.89M -13.22M -5.18M -65.23M -4.96M -4.86M -209M
Projected Income Statement - Annual - Interpace Biosciences, Inc.
Logo Interpace Biosciences, Inc.
Interpace Biosciences, Inc. provides esoteric molecular diagnostic testing and pathology services to aid physicians in the evaluation of cancer risk. The Company’s clinical services business commercializes clinically useful molecular diagnostic tests and molecular pathology services. The Company develops and commercializes genomic tests and related first-line assays that can personalize medicine to help improve patient diagnosis and management. It has five commercialized molecular diagnostic tests: PancraGEN, PanDNA, ThyGeNEXT, ThyraMIR v2, and RespriDX. PancraGEN is a pancreatic cyst and pancreaticobiliary solid lesion genomic test that helps physicians’ better risk-stratify pancreaticobiliary cancers using the Company’s proprietary PathFinderTG platform. PanDNA is an alternate reporting option of the PathFinderTG platform, which provides physicians the molecular only information. ThyGeNEXT is an oncogenic mutation panel that helps rule-in and rule-out malignancy in thyroid nodules.
Employees
102
Date Price Change Volume
26-10-09 $6.000 0.00% 410
26-10-07 $6.000 -0.41% 354

Annual profits - Rate of surprise

Rate of surprise - EPS - Annual - Interpace Biosciences, Inc.
  1. Stock Market
  2. Stocks
  3. IDXG Stock